These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
153 related articles for article (PubMed ID: 2973769)
1. [Chemo-endocrine therapy of advanced breast cancer]. Nomura Y Gan To Kagaku Ryoho; 1988 Dec; 15(12):3214-20. PubMed ID: 2973769 [TBL] [Abstract][Full Text] [Related]
2. [A randomized trial of endocrine therapy, chemotherapy, and chemo-endocrine therapy in advanced breast cancer]. Tashiro H; Nomura Y; Hisamatsu K Gan To Kagaku Ryoho; 1990 Dec; 17(12):2369-73. PubMed ID: 2260873 [TBL] [Abstract][Full Text] [Related]
3. [Breast cancer and hormone therapy]. Izuo M Gan To Kagaku Ryoho; 1987 Oct; 14(10):2830-6. PubMed ID: 2959203 [TBL] [Abstract][Full Text] [Related]
4. Tamoxifen therapy of metastatic breast cancer. Manni A J Lab Clin Med; 1987 Mar; 109(3):290-9. PubMed ID: 2950193 [TBL] [Abstract][Full Text] [Related]
5. [Progress in breast cancer chemo-endocrine therapy from the survival standpoint]. Nomura Y Gan To Kagaku Ryoho; 1995 May; 22(6):726-31. PubMed ID: 7755380 [TBL] [Abstract][Full Text] [Related]
6. [Present status of endocrine therapy of breast cancer: a surgeon's view]. Nomura Y Gan To Kagaku Ryoho; 1984 May; 11(5):981-8. PubMed ID: 6426405 [TBL] [Abstract][Full Text] [Related]
7. Content of epidermal growth factor receptor in metastatic breast cancer: its role in endocrine sensitivity prediction. Nesković-Konstantinović ZB; Nikolić-Vukosavljević DB; Branković-Magić MV; Mitrovic LB; Spuzić I Neoplasma; 2000; 47(2):107-13. PubMed ID: 10985476 [TBL] [Abstract][Full Text] [Related]
8. [Chemo-endocrine therapy with high dose medroxyprogesterone acetate for recurrent or advanced breast cancer]. Maeda T; Kubo Y; Sasajima T; Ikeda K; Hirata S; Yamazaki K; Nakajima S Gan To Kagaku Ryoho; 1993 Nov; 20(14):2165-9. PubMed ID: 8239681 [TBL] [Abstract][Full Text] [Related]
9. Chemoendocrine compared with endocrine adjuvant therapies for node-negative breast cancer: predictive value of centrally reviewed expression of estrogen and progesterone receptors--International Breast Cancer Study Group. Viale G; Regan MM; Maiorano E; Mastropasqua MG; Golouh R; Perin T; Brown RW; Kovács A; Pillay K; Ohlschlegel C; Braye S; Grigolato P; Rusca T; Gelber RD; Castiglione-Gertsch M; Price KN; Goldhirsch A; Gusterson BA; Coates AS J Clin Oncol; 2008 Mar; 26(9):1404-10. PubMed ID: 18349391 [TBL] [Abstract][Full Text] [Related]
10. [Hormone therapy of breast cancer-its role in the treatment of breast cancer]. Koyama H; Shiba E Gan No Rinsho; 1985 Jul; 31(9 Suppl):1177-81. PubMed ID: 2932568 [TBL] [Abstract][Full Text] [Related]
11. [Effects of high-dose medroxyprogesterone acetate in advanced breast cancer, with special reference to prior endocrine therapy and hormone receptors]. Nomura Y; Tashiro H; Hisamatsu K; Toi M Gan To Kagaku Ryoho; 1988 Mar; 15(3):513-8. PubMed ID: 2964811 [TBL] [Abstract][Full Text] [Related]
12. [Endocrine therapy of recurrent breast cancer]. Nomura Y; Tashiro H Gan To Kagaku Ryoho; 1985 Mar; 12(3 Pt 1):421-7. PubMed ID: 3890756 [TBL] [Abstract][Full Text] [Related]
13. Primary endocrine therapy in locally advanced breast cancers--the Nottingham experience. Mathew J; Agrawal A; Asgeirsson KS; Buhari SA; Jackson LR; Cheung KL; Robertson JF Breast Cancer Res Treat; 2009 Jan; 113(2):403-7. PubMed ID: 18311583 [TBL] [Abstract][Full Text] [Related]
14. [A controlled study with medroxyprogesterone acetate (MPA) alone or in combination with cyclophosphamide (CPA) in the treatment of advanced or recurrent breast cancer unresponsive to other therapies. Osaka Study Group for the Treatment of Breast Cancer]. Aikawa T; Yayoi E; Takatsuka Y; Maeura Y; Miyauchi K Gan To Kagaku Ryoho; 1991 May; 18(6):995-1002. PubMed ID: 1827575 [TBL] [Abstract][Full Text] [Related]
15. [Value of hormone therapy in metastasizing breast cancer]. Samonigg H Wien Med Wochenschr; 1985 Dec; 135(23-24):602-7. PubMed ID: 2937208 [TBL] [Abstract][Full Text] [Related]
16. Response to second line chemo-endocrine treatment may prolong the overall survival of advanced breast cancer patients. Nomura Y Anticancer Res; 1997; 17(2B):1425-30. PubMed ID: 9137509 [TBL] [Abstract][Full Text] [Related]
17. Adjuvant hormonal therapy for premenopausal women with breast cancer. Brown RJ; Davidson NE Semin Oncol; 2006 Dec; 33(6):657-63. PubMed ID: 17145345 [TBL] [Abstract][Full Text] [Related]
18. [Effectiveness of combination hormonal therapies in advanced or recurrent breast cancer--a randomized trial of tamoxifen (TAM), medroxyprogesterone acetate (MPA), their simultaneous combination, and an alternating sequential combination of TAM plus MPA]. Sonoo H; Senoo T; Nishiki M; Morimoto T; Takashima S Gan To Kagaku Ryoho; 1996 Mar; 23(4):447-54. PubMed ID: 8678496 [TBL] [Abstract][Full Text] [Related]
19. [Sequential therapy with antiestrogens and progestational drugs in carcinoma of the breast in an advanced stage]. Palmeri R; Papalia E; Lazzara S; Belnome NA; Gorgone S; Calbo E; Melita P Chir Ital; 1987 Apr; 39(2):185-92. PubMed ID: 2958166 [TBL] [Abstract][Full Text] [Related]
20. [Estrogen antagonists and inhibitors in hormone therapy of breast cancer]. Dryzhak VI Vopr Onkol; 1989; 35(7):771-8. PubMed ID: 2528239 [No Abstract] [Full Text] [Related] [Next] [New Search]